Video

ecancer's extensive video archive features interviews, panel discussions and conference coverage on almost every topic in oncology.

HER2 status as predictive marker for aromatase inhibitor versus tamoxifen use in early breast cancer

Dr John Bartlett - Ontario Institute for Cancer Research, Toronto, Canada
HER2 status as predictive marker for aromatase inhibitor versus tamoxifen use in early breast cancer ( Dr John Bartlett -  Ontario Institute for Cancer Research, Toronto, Canada )
17 Dec 2015

Trastuzumab emtansine improves overall survival versus treatment of physician's choice in patients with previously treated HER2-positive metastatic breast cance

Prof Hans Wildiers - University Hospital of Leuven, Leuven, Belgium
Trastuzumab emtansine improves overall survival versus treatment of physician's choice in patients with previously treated  HER2-positive metastatic breast cance ( Prof Hans Wildiers - University Hospital of Leuven, Leuven, Belgium )
17 Dec 2015

Homologous recombination deficiency predicts neo-adjuvant chemotherapy response in triple-negative breast cancer

Dr Virginia Kaklamani - UT Health Science Center, San Antonio, TX
Homologous recombination deficiency predicts neo-adjuvant chemotherapy response in triple-negative breast cancer ( Dr Virginia Kaklamani - UT Health Science Center, San Antonio, TX )
17 Dec 2015

TAILORx: Genomic test helps identify low-risk women who do not need chemotherapy

Dr Virginia Kaklamani - UT Health Science Center, San Antonio, TX
TAILORx: Genomic test helps identify low-risk women who do not need chemotherapy ( Dr Virginia Kaklamani - UT Health Science Center, San Antonio, TX )
17 Dec 2015

Efficacy and gene expression results from eribulin SOLTI1007 neoadjuvant study

Dr Javier Cortes - Vall d´Hebron Institute of Oncology, Barcelona, Spain
Efficacy and gene expression results from eribulin SOLTI1007 neoadjuvant study ( Dr Javier Cortes - Vall d´Hebron Institute of Oncology, Barcelona, Spain )
17 Dec 2015

ER and FGFR1 interaction critical in endocrine resistant breast cancer

Dr Luigi Formisano - Vanderbilt University Nashville, USA
ER and FGFR1 interaction critical in endocrine resistant breast cancer ( Dr Luigi Formisano - Vanderbilt University Nashville, USA )
16 Dec 2015

Interrupting breast cancer treatment for young women who desire pregnancy

Dr Olivia Pagani and Dr Ann Partridge
Interrupting breast cancer treatment for young women who desire pregnancy ( Dr Olivia Pagani and Dr Ann Partridge )
16 Dec 2015

Editor's choice for December 2015

Prof Gordon McVie - ecancer Editor
Editor's choice for December 2015 ( Prof Gordon McVie - ecancer Editor )
16 Dec 2015

Treatment outcomes in patients with invasive breast cancer treated with neoadjuvant systemic therapy and breast MR imaging

Prof Jennifer De Los Santos - University of Alabama, Birmingham, USA
Treatment outcomes in patients with invasive breast cancer treated with neoadjuvant systemic therapy and breast MR imaging ( Prof Jennifer De Los Santos - University of Alabama, Birmingham, USA )
15 Dec 2015

Novel estrogen receptor-targeting agent represents ‘quantum leap’

Dr Ganesh Raj - UT Southwestern Medical Center, Dallas, USA
Novel estrogen receptor-targeting agent represents ‘quantum leap’ ( Dr Ganesh Raj - UT Southwestern Medical Center, Dallas, USA )
15 Dec 2015

Ductal carcinoma in situ: Anastrozole versus tamoxifen

Dr Terry Mamounas - UF Health Cancer Center, Orlando, USA
Ductal carcinoma in situ: Anastrozole versus tamoxifen ( Dr Terry Mamounas - UF Health Cancer Center, Orlando, USA )
15 Dec 2015

Update on management of the axilla

Dr Terry Mamounas - UF Health Cancer Center, Orlando, USA
Update on management of the axilla ( Dr Terry Mamounas - UF Health Cancer Center, Orlando, USA )
14 Dec 2015